HIGH-INCIDENCE OF MYELOPROLIFERATIVE DISORDERS IN ASHKENAZI JEWS IN NORTHERN ISRAEL

被引:42
作者
CHAITER, Y [1 ]
BRENNER, B [1 ]
AGHAI, E [1 ]
TATARSKY, I [1 ]
机构
[1] RAMBAM MED CTR,INST HEMATOL,DEPT HEMATOL,POB 9602,IL-31096 HAIFA,ISRAEL
关键词
MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; AGNOGENIC MYELOID; METAPLASIA; THROMBOCYTHEMIA;
D O I
10.3109/10428199209053630
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have analysed epidemiological parameters in 339 patients with myeloproliferative disorders (MPD) diagnosed in northern Israel between 1975 and 1989 as having polycythemia vera (191 patients), agnogenic myeloid metaplasia (AMM) (113) and essential thrombocythemia (ET) (36). Mean average annual incidence was 11.4 per 1 million residents for polycythemia vera, 6.5 for AMM and 2.1 for ET. For all three diseases the average annual incidence increased with age and was 10 times higher in patients over 65 years compared to those less under the age of 45 years. Four percent of all patients had relatives with MPD. Incidence of MPD in Jews was 10 fold higher than expected compared to Arabs and this difference was noted for all 3 diseases. The incidence in Ashkenazi Jews originating from eastern and central Europe, was 10 and 20 folds higher than in Sephardic Jews and Arabs respectively. Mean age at diagnosis of MPD in Arabs and Sephardic Jews was lower than in Ashkenazi Jews (52 and 56 years compared to 64 years P < 0.05). Likewise, mean age at diagnosis was lower in the 11.5% of MPD patients with prior exposure to biological or chemical hazards compared to unexposed individuals (58 years versus 63 years, P < 0.02). These data demonstrate a cluster of MPD in Ashkenazi Jews in northern Israel and emphasize the importance of genetic predisposition possibly interacting with acquired factors in the pathogenesis of these disorders.
引用
收藏
页码:251 / 255
页数:5
相关论文
共 25 条
[1]  
Adamson J.W., Fialkow P.J., Murphy S., Prchal J.F., Steinmann T., Polycythemia vera: Stem cell and probable clonal origin of the disease, New England Journal of Medicine, 295, (1976)
[2]  
Silverstein M.N., Agnogenic myeloid metaplasia, Hematology, 3rd edition, pp. 214-217, (1986)
[3]  
Tobelem G., Essential thrombocythemia, Baillieres Clin. Hematol, 2, (1989)
[4]  
Modan B., An epidemiological study of polycythemia vera, Blood, 26, (1965)
[5]  
Silverstein M.N., Lanier A.P., Polycythemia vera 1935-1969-an epidemiologic survey in Rochester, Minnesota, Mayo. clin. Proc, 46, (1971)
[6]  
Prochazka A.V., Markowe H.L.J., The epidemiology of polycythaemia rubra vera in England and Wales 1968-1982, British Journal of Cancer, 53, (1986)
[7]  
Dougan L.E., Mattheus M.V.L., Armstrong B.K., The effect of diagnostic review on the incidence of lymphatic and hematopoietic neoplasms in Western Australia, Cancer, 48, (1981)
[8]  
Mattila K., Primaarisen polystemian esintyminen suomessa, Duodecim., 97, (1981)
[9]  
Modan B., Kalliner M., Lemer D., Yoran C., A note on the increased risk of polycythemia vera in Jews, Blood, 37, (1977)
[10]  
Najean Y., Mognier P., Oresch C., Rain J.D., Polycythemia vera in young people: An analysis of 58 cases diagnosed before 40 years, British Journal of Haematology, 67, (1987)